The University of Birmingham is leading researchers as they investigate whether a GLP-1 agonist drug
, which is currently used to lower blood sugar in people with type II diabetes, could be repurposed to treat raised brain pressure, Pharma Times reported on Thursday.
Hauser found that PD patients who failed to obtain good symptom control after taking a certain dopamine agonist drug
, such as apomorphine (Apokyn), pramipexole (Mirapex), or ropinirole (Requip), achieved much greater symptom relief by taking the commonly prescribed PD drug rasagiline (Azilect).
Mark Robson, 56, became obsessed with gambling after taking the dopamine agonist drug
to control the symptoms of Parkinson's.
s dopamine agonist drug
indicated for the acute, intermittent treatment of so-called off episodes in patients suffering from motor complications associated with advanced Parkinson's disease.
The GLP-1 receptor agonist drug
class - including Novo Nordisk's Victoza and Amylin/Alkermes's Bydureon - is forecasted to earn the second highest sales in the market over the next five years.
Bremelanotide, which is a melanocortin 4 receptor agonist drug
candidate, is a synthetic peptide analog of the naturally occurring hormone alpha-MSH (melanocyte-stimulating hormone).
s Maxalt-MLT(R), a leading, approved, migraine treatment, based on Rizatriptan, a 5-HT1 receptor agonist drug
Food and Drug Administration to restrict the availability of GlaxoSmithKline's Avandia in the United States and a ruling by the European Medicines Agency to withdraw the drug in Europe will cause Avandia to lose almost all its sales, leaving Takeda's Actos as the predominant representative of the PPAR-gamma agonist drug
class on the market.
LOS ANGELES -- ConjuChem, LLC, a biotechnology company dedicated to the discovery of novel therapeutics, today announced it has initiated patient enrollment for its Phase 2 clinical trial of its proprietary GLP-1 receptor agonist drug
, CJC-1134-PC, in patients with Type 2 diabetes mellitus who are receiving metformin monotherapy.
The first GLP1 agonist drug
, Exenatide (Byetta), was approved in 2005, and has already reached sales of over $670 million.
In conjunction with the data presentation, Idera announced the selection of this compound as its lead TLR7/TLR8 agonist drug
candidate for the treatment of hematological malignancies.
I am particularly interested in the pace of development of Synergy's GC-C receptor agonist drug
SP-304 to treat GI disorders which is poised to move forward in the clinic in early 2010.